Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated:  2/12/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated: 2/12/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)
Status: Enrolling
Updated:  2/12/2016
Rockefeller University
mi
from
New York, NY
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)
Status: Enrolling
Updated: 2/12/2016
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
A Novel Neurorehabilitation Approach for Cognitive Aging With HIV
Speed of Processing Training With Transcranial Direct Current Stimulation in Older HIV+ Adults (HtDCS)
Status: Enrolling
Updated:  2/14/2016
UAB 1917 Clinic
mi
from
Birmingham, AL
A Novel Neurorehabilitation Approach for Cognitive Aging With HIV
Speed of Processing Training With Transcranial Direct Current Stimulation in Older HIV+ Adults (HtDCS)
Status: Enrolling
Updated: 2/14/2016
UAB 1917 Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Status: Enrolling
Updated:  2/16/2016
University of Pennsylvania, Treatment Research Center
mi
from
Philadelphia, PA
Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Status: Enrolling
Updated: 2/16/2016
University of Pennsylvania, Treatment Research Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intervention Targeting Substance Using Older Adults With HIV
Intervention Targeting Substance Using Older Adults With HIV
Status: Enrolling
Updated:  2/17/2016
Center for HIV/AIDS Educational Studies and Training of Hunter College, CUNY
mi
from
New York, NY
Intervention Targeting Substance Using Older Adults With HIV
Intervention Targeting Substance Using Older Adults With HIV
Status: Enrolling
Updated: 2/17/2016
Center for HIV/AIDS Educational Studies and Training of Hunter College, CUNY
mi
from
New York, NY
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Department of Ophthalmology, University of California, Irvine
mi
from
Irvine, CA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Department of Ophthalmology, University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Shiley Eye Center Center, 0946, University of California, San Diego
mi
from
La Jolla, CA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Shiley Eye Center Center, 0946, University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
LAC/USC Medical Center, 5P21 Rand Schrader Clinic
mi
from
Los Angeles, CA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
LAC/USC Medical Center, 5P21 Rand Schrader Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Jules Stein Eye Institute, University of California, Los Angeles
mi
from
Los Angeles, CA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Jules Stein Eye Institute, University of California, Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Beckman Vision Center, University of California, San Francisco
mi
from
San Francisco, CA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Beckman Vision Center, University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
University of South Florida, MDC Box 21
mi
from
Tampa, FL
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
University of South Florida, MDC Box 21
mi
from
Tampa, FL
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
The Emory Clinic, Emory University
mi
from
Atlanta, GA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
The Emory Clinic, Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Department of Ophthalmology, Northwestern University
mi
from
Chicago, IL
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Department of Ophthalmology, Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Division of Infectious Diseases, Indiana University, Indianapolis
mi
from
Indianapolis, IN
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Division of Infectious Diseases, Indiana University, Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
LSU Eye Center, Louisiana State University Medical Center
mi
from
New Orleans, LA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
LSU Eye Center, Louisiana State University Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Harvard/BCH AIDS Clinical Trials Unit, Massachusetts General Hospital
mi
from
Boston, MA
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Harvard/BCH AIDS Clinical Trials Unit, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
UMDNJ-New Jersey Medical School
mi
from
Newark, NJ
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
UMDNJ-New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Department of Ophthalmology, New York University Medical Center
mi
from
New York, NY
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Department of Ophthalmology, New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Department of Ophthalmology, New York Hospital-Cornell Medical Center
mi
from
New York, NY
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Department of Ophthalmology, New York Hospital-Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated:  2/18/2016
Cullen Eye Institute, Baylor College of Medicine
mi
from
Houston, TX
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Status: Enrolling
Updated: 2/18/2016
Cullen Eye Institute, Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Intrauterine Insemination In HIV-Discordant Couples
Intrauterine Insemination In HIV-Discordant Couples
Status: Enrolling
Updated:  2/19/2016
Boston Med Ctr
mi
from
Boston, MA
Intrauterine Insemination In HIV-Discordant Couples
Intrauterine Insemination In HIV-Discordant Couples
Status: Enrolling
Updated: 2/19/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy
Status: Enrolling
Updated:  2/22/2016
Johns Hopkins University
mi
from
Baltimore, MD
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy
Status: Enrolling
Updated: 2/22/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Status: Enrolling
Updated:  2/22/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Status: Enrolling
Updated: 2/22/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Health for Life Clinic, PLLC
mi
from
Little Rock, AR
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Health for Life Clinic, PLLC
mi
from
Little Rock, AR
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Living Hope Clinical Foundation
mi
from
Long Beach, CA
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Living Hope Clinical Foundation
mi
from
Long Beach, CA
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Georgetown University
mi
from
Washington,
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Clinical Research of West Florida
mi
from
Clearwater, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Clinical Research of West Florida
mi
from
Clearwater, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Associates in Research, Inc.
mi
from
Fort Myers, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Associates in Research, Inc.
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Steinhart Medical Associates
mi
from
Miami, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Steinhart Medical Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
University of Miami School of Medicine
mi
from
Miami, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Orlando Immunology Center
mi
from
Orlando, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Hillsborough County Health Department
mi
from
Tampa, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Hillsborough County Health Department
mi
from
Tampa, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Infectious Disease Research Institute, Inc.
mi
from
Tampa, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Infectious Disease Research Institute, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Triple O Medical Services, P.A.
mi
from
West Palm Beach, FL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Triple O Medical Services, P.A.
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Northwestern University
mi
from
Chicago, IL
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
University of Kansas School of Medicine - Wichita
mi
from
Wichita, KA
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
University of Kansas School of Medicine - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Georgetown University
mi
from
Washington D.C., MD
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Georgetown University
mi
from
Washington D.C., MD
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
CRI of New England
mi
from
Boston, MA
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
CRI of New England
mi
from
Boston, MA
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Saint Michael's Medical Center
mi
from
Newark, NJ
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Saint Michael's Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Beth Israel Med Ctr
mi
from
New York, NY
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Central Texas Clinical Research
mi
from
Austin, TX
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Central Texas Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Nicholaos C. Bellos, MD
mi
from
Dallas, TX
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Nicholaos C. Bellos, MD
mi
from
Dallas, TX
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Therapeutic Concepts, P.A.
mi
from
Houston, TX
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Therapeutic Concepts, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
University of Texas Health Science Center
mi
from
Houston, TX
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated:  2/22/2016
Thomas Street Clinic
mi
from
Houston, TX
Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.
Status: Enrolling
Updated: 2/22/2016
Thomas Street Clinic
mi
from
Houston, TX
Click here to add this to my saved trials